ALX Oncology, Merck to Collaborate on Head and Neck Cancer Treatment Trials
September 22 2020 - 8:06AM
Dow Jones News
By Chris Wack
ALX Oncology Holdings Inc. said Tuesday it is collaborating with
Merck & Co. to evaluate the combination of ALX148 and Keytruda
for treating patients with a certain type of head and neck
cancer.
Under the terms of the agreement, ALX Oncology will conduct two
Phase 2 studies. The first will evaluate the efficacy of ALX148, an
investigational next generation CD47 blocker, in combination with
Merck's drug to treat patients with PD-L1 expressing metastatic or
unresectable, recurrent head and neck squamous cell carcinoma.
The second study will evaluate ALX148, Keytruda and standard
chemotherapy to treat patients with metastatic or unresectable,
recurrent HNSCC.
ALX Oncology owns worldwide commercial rights to ALX148.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 22, 2020 07:51 ET (11:51 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024